Minocycline in Huntington's disease: A pilot study

Authors

  • Madhavi Thomas MD,

    Corresponding author
    1. Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    • Clinical Pharmacology Section, Experimental Therapeutics Branch, Building 10 room 5C 103, 10 Center Drive, Bethesda, MD 20892-146
    Search for more papers by this author
  • Tetsuo Ashizawa MD,

    1. Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA
    Search for more papers by this author
  • Joseph Jankovic MD

    1. Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Search for more papers by this author

Abstract

Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society

Ancillary